TYRA
Tyra Biosciences, Inc.
Biotechnology · Healthcare · United States
21.07
close · 2026-10-30
value
88
cheaper than peers88
quality
79
stronger fundamentals79
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | -6.3% | 83 |
| earnings yield, 1 year ago | -7.2% | 79 |
| earnings yield, 2 years ago | -7.7% | 78 |
| cash flow yield, 2 years ago | -3.5% | 77 |
| cash flow yield, 1 year ago | -4.9% | 75 |
| cash flow yield, latest year | -6.6% | 74 |
| earnings yield, latest year | -9.5% | 72 |
| cash flow yield, 3 years ago | -3.5% | 71 |
| price to book | 3.55× | 40 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -36.9% | 79 |
| debt to equity | 1.5% | 65 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $1B |
| free cash flow | -$60.1M |
| employees | 87 |
| first trade | 2021-09-15 |
| next earnings | not reported |
| fundamentals updated | 2026-08-05 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -2.01 | -1.51 | -1.62 | -1.32 |
| free cash flow | -$95.3M | -$70.4M | -$50.9M | -$50.8M |
| net income | -$119.9M | -$86.5M | -$69.1M | -$55.3M |
| revenue | $0 | $0 | $0 | $0 |